

T cell response	no	yes	p
n	19	26	
Age (mean (SD))	65.45 (10.45)	63.05 (14.40)	0.540
Gender: female (%)	13 (68.4)	22 (84.6)	0.281
Diagnosis n (%)			0.315
IgG4-related Disease	2 (10.5)	0 (0.0)	
Connective Tissue Disease	4 (21.1)	8 (30.8)	
Rheumatoid Arthritis	9 (47.4)	15 (57.7)	
Vasculitis	4 (21.1)	3 (11.5)	
Peripheral B cells, absolute (median [IQR])	0.00 [0.00, 4.50]	9.50 [0.00, 33.75]	0.049
Detectable B cells (%)	7 (36.8)	16 (61.5)	0.182
IgG (median [IQR]) mg/dL	743 [642, 954]	779 [634, 1045]	0.611
IgM (median [IQR]) mg/dL	45 [27, 61]	48 [25, 73]	0.937
Months between RTX and Vaccination (mean (SD))	5 (1.8)	7.3 (6.6)	0.139
Days between Vaccine and Laboratory assessment (mean (SD))	16.0 (10.4)	16.7 (11.7)	0.859
Concomitant Medication n (%)			
Any csDMARD	10 (52.6)	15 (57.7)	0.770
Methotrexate	5 (26.3)	11 (42.3)	0.351
Mycophenolate Mofetil	1 (5.3)	2 (7.7)	1.000
Leflunomide	1 (5.3)	2 (7.7)	1.000
Hydroxychloroquine	2 (10.5)	1 (3.8)	0.565
Azathioprine	2 (10.5)	0 (0.0)	0.173
Sulfasalazine	1 (5.3)	0 (0.0)	0.422
Immunoglobulin therapy	0 (0.0)	2 (7.7)	0.501
Prednisone	6 (31.6)	6 (23.1)	0.734
Vaccine n (%)			1.000
mRNA-1273	3 (15.8)	5 (19.2)	
BNT162b2	16 (84.2)	21 (80.8)	
Seroconversion n (%)	6 (31.6)	12 (46.2)	0.371
SARS Cov2-S Antibodies U/ml (median [IQR])	0.0 [0.0, 2.6]	0.0 [0.0, 249.5]	0.113

Mean T cell response per SFCs/10 ⁶ PBMCs	12.67 (12.71)	263.12 (136.91)	<0.001
---	---------------	-----------------	------------------

Supplemental Table 3: Patient characteristics stratified by T cell response